Publication:
Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension

dc.contributor.coauthorAfsar, Baris
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.kuauthorÖnal, Emine Meltem
dc.contributor.kuauthorSağ, Alan Alper
dc.contributor.kuauthorŞal, Oğuzhan
dc.contributor.kuauthorYerlikaya, Aslıhan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:34:22Z
dc.date.issued2017
dc.description.abstractOrgan crosstalk pathways represent the next frontier for target-mining in molecular medicine for existing syndromes. Pulmonary hypertension and resistant essential hypertension are syndromes that have been proven elusive in etiology, and frequently refractory to first-line management. Underlying crosstalk mechanisms, not yet considered in these treatments, may hinder outcomes or unlock novel treatments. This review focuses systematically on erythropoietin, a synthesizable molecule, as a mediator of brain-kidney crosstalk. Insights gained from this review will be applied to cardiovascular diseases in a clinician-directed fashion.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue3
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume39
dc.identifier.doi10.1080/10641963.2016.1246565
dc.identifier.eissn1525-6006
dc.identifier.issn1064-1963
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85018312749
dc.identifier.urihttps://doi.org/10.1080/10641963.2016.1246565
dc.identifier.urihttps://hdl.handle.net/20.500.14288/12341
dc.identifier.wos400341300001
dc.keywords(MeSH) Crosstalk
dc.keywordsErythropoietin
dc.keywordsHypertension
dc.keywordsMolecular medicine
dc.keywordsRecombinant-human-erythropoietin
dc.keywordsNitric-oxide synthase
dc.keywordsRenin-angiotensin-aldosterone
dc.keywordsChronic-hemodialysis patients
dc.keywordsEndothelial progenitor cells
dc.keywordsAnalog darbepoetin-alpha
dc.keywordsSmooth-muscle-cells
dc.keywordsAcute lung injury
dc.keywordsBlood-pressure
dc.keywordsBarrier disruption
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.ispartofClinical and Experimental Hypertension
dc.subjectPharmacology
dc.subjectPharmacy
dc.subjectPeripheral vascular disease
dc.titleErythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorKanbay, Mehmet
local.contributor.kuauthorÖnal, Emine Meltem
local.contributor.kuauthorSağ, Alan Alper
local.contributor.kuauthorŞal, Oğuzhan
local.contributor.kuauthorYerlikaya, Aslıhan
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files